Neogene Therapeutics Raises $110 Million Series A Financing to Develop Next-Generation Fully Personalized Neo-Antigen T Cell Receptor (TCR) Therapies Series A Financing led by EcoR1 Capital, Jeito Capital and Syncona with continued support of strategic seed investors Vida Ventures, TPG and Two River Neogene’s proprietary technology platform identifies specific T cell receptor (TCR) genes from routine tumor samples using state-of-the-art synthetic biology tools Co-founded by renowned T cell engineering expert Ton Schumacher, Ph.D. and Carsten Linnemann, Ph.D. with investment from cell therapy industry veteran Arie Belldegrun, M.D.